Bristol Myers Squibb

@bmsnews

We work every day to transform patients’ lives through science. See our community guidelines: one.bms.com/3WHdbIG

New York, New York

Bristol Myers Squibb
@bmsnews
Sep 17
#MEDIA: Today at #CCRWest2026, we announced two-year results from the Phase 3 study evaluating an approved medicine for adults with active #PsoriaticArthritis (PsA). Read more: bit.ly/4AnsaKQ
Bristol Myers Squibb
@bmsnews
Sep 8
#MEDIA: Announcing positive topline results from a Phase 2 trial of an investigational #CARTCellTherapy for certain patients with relapsed or refractory multiple myeloma. bit.ly/4gJ1FYA
2
Bristol Myers Squibb
@bmsnews
Aug 29
#MEDIA: At the 2026 #ESCCongress, we shared new long-term and real-world data in adults with symptomatic obstructive hypertrophic cardiomyopathy, adding to real-world evidence on long-term outcomes for this patient population: bit.ly/4yd4dEb
3
Bristol Myers Squibb
@bmsnews
Aug 27
We're investing more than $173 million to expand U.S. radiopharmaceutical manufacturing capacity and help deliver next-generation cancer treatments to patients. Led by @RayzeBio, this investment will support jobs and innovation in Indiana. bit.ly/4qLAi3u #OneBMS
Bristol Myers Squibb
@bmsnews
Aug 13
#MEDIA: @US_FDA granted accelerated approval to our new CELMoD treatment for relapsed or refractory #MultipleMyeloma in adults, introducing a new class of treatment. bit.ly/45s9hrO
00:00
4